Eli Lilly and Company (LLY)
Eli Lilly Advances Alzheimer's Solutions With Kisunla Approval
Eli Lilly's new Alzheimer's drug, Kisunla, shows promise with its unique treatment regimen and potential competitive advantages over Biogen's Leqembi. Despite challenges, Kisunla is priced aggressively at $32,000 per year, offering a potentially more cost-effective solution given its shorter treatment duration. Eli Lilly reported a 26% increase in revenue in Q1, driven by strong performances from its diabetes and obesity drugs.
Eli Lilly's Alzheimer's drug receives FDA sign-off
The Food and Drug Administration (FDA) has approved Eli Lilly and Co's (NYSE:LLY) new Alzheimer's drug, donanemab, to be sold under the brand name Kisunla. This monoclonal antibody infusion, administered every four weeks, targets amyloid in the brain, a hallmark of Alzheimer's disease.
Novo Nordisk and Eli Lilly Slide as Biden Blasts Weight-Loss Drug Prices
Novo Nordisk (NVO) American depositary receipts (ADRs) and Eli Lilly (LLY) shares lost ground Tuesday after U.S. President Joe Biden and Senator Bernie Sanders called out the companies in an op-ed for the cost of their medicines.
Eli Lilly's Alzheimer's drug wins FDA approval
An Eli Lilly & Co. Alzheimer's drug won Food and Drug Administration approval Tuesday, capping the medication's bumpy ride through the U.S. regulatory process and adding a second new treatment option for patients in earlier stages of the disease.
FDA Approves Eli Lilly's Alzheimer's Drug Donanemab
The Food and Drug Administration on Tuesday approved donanemab for treating Alzheimer's disease, after clinical studies indicated Eli Lilly's drug could significantly slow cognitive decline, following years of delays to get the experimental treatment to market.
FDA approves Eli Lilly Alzheimer's drug, expanding treatment options in the U.S.
The Food and Drug Administration approved Eli Lilly's Alzheimer's drug donanemab, expanding the limited treatment options for the mind-wasting disease. It's a long-awaited win for Eli Lilly after donanemab faced several delays in its path to market.
US FDA approves Lilly's Alzheimer's drug
The U.S. Food and Drug Administration on Tuesday gave a green light to Eli Lilly's donanemab for patients with early Alzheimer's, making it the second approved drug for slowing the progress of the brain-wasting disease.
Approval of Newest Alzheimer's Drug Will Accelerate New Era of Treatment
The approval Tuesday of Eli Lilly's LLY -0.53%decrease; red down pointing triangle new Alzheimer's drug will hasten the transformation of treatment of the dementia-causing condition.
Novo, Lilly Dive After Biden Slams Duo For 'Unconscionably High' Drug Prices
Novo Nordisk stock fell Tuesday after Joe Biden and Bernie Sanders slammed the drugmaker and Eli Lilly for high prices of weight-loss drugs.
Eli Lilly Soars To 52-Week High: Can The Momentum Continue?
Eli Lilly and Company LLY has hit a new 52-week high, climbing to $915.54 during Friday trading. The stock is up a remarkable 97.38% over the past year and 55.32% year-to-date, fueled by groundbreaking collaborations and bullish technical indicators.
India panel urges drug regulator to approve Lilly's obesity drug Mounjaro
An Indian government-approved expert panel has advised the country's drug regulator to approve the import and sale of U.S. drugmaker Eli Lilly's Mounjaro, a blockbuster diabetes drug and a wildly popular obesity treatment, a document on a government website showed on Monday.
Want Decades of Passive Income? 2 Top Dividend Stocks to Buy Now and Hold Forever.
Secured by a $159 billion order backlog, Lockheed Martin's dividend payments are as dependable as they get. Eli Lilly can help you cash in on the booming $130 billion weight-loss drug market.
